AR092266A1 - Inhibidores de ddr2 para el tratamiento de osteoartritis - Google Patents
Inhibidores de ddr2 para el tratamiento de osteoartritisInfo
- Publication number
- AR092266A1 AR092266A1 ARP130103053A ARP130103053A AR092266A1 AR 092266 A1 AR092266 A1 AR 092266A1 AR P130103053 A ARP130103053 A AR P130103053A AR P130103053 A ARP130103053 A AR P130103053A AR 092266 A1 AR092266 A1 AR 092266A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- hal
- independently selected
- mono
- carbon atoms
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 abstract 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Compuestos de la fórmula (1), en donde W es O, N, CH₂, CH₂CH₂, CH₂CHOH o -(CH₂)O-; X, Y, Q, U, T son, de modo independiente entre sí, C o N, siempre que uno o varios de X, Y, Q, U y T sean átomos de carbono y que M esté ligado a un átomo de carbono; V es un enlace simple o -CR⁴R⁵-; M es O ó -CR⁴R⁵-; R¹ es heteroarilo, heterociclilo o arilo mono- o bicíclico que contiene 3 a 14 átomos de carbono y 1 ó 4 heteroátomos, seleccionados de modo independiente de N, O y S, que no está sustituido o que está mono-, di- o trisustituido con R⁶; R² es H, A, CN, OH, OA o Hal; R³ es heteroarilo, heterociclilo o arilo mono- o bicíclico que contiene 3 a 14 átomos de carbono y 1 ó 4 heteroátomos, seleccionados de modo independiente de N, O y S, que no está sustituido o que está mono-, di- o trisustituido con R⁷; R⁴, R⁵ están seleccionados, de modo independiente entre sí, del grupo que consiste en H y A; R², R⁶ y R⁷ están seleccionados, de modo independiente entre sí, del grupo que consiste en H, A, =O, OH, OA, Hal, CH₂HaI, CH(Hal)₂, C(Hal)₃, NO₂, (CH₂)ₙCN, (CH₂)ₙNR⁸R⁹, (CH₂)ₙO(CH₂)ₖNR⁸R⁹, (CH₂)ₙNR⁸(CH₂)ₖNR⁸R⁹, (CH₂)ₙO(CH₂)ₖOR¹⁸, (CH₂)ₙNR⁸(CH₂)ₖOR⁹, (CH₂)ₙCOOR¹⁰, (CH₂)ₙCHOR¹⁰, (CH₂)ₙCHONR⁸R⁹, C(O)NR⁸R⁹, C(O)NHANH₂, (CH₂)ₙNR⁸COR¹⁰, (CH₂)ₙNR⁸CONR⁸R⁹, (CH₂)ₙNR⁸SO₂A, (CH₂)ₙSO₂NR⁸R⁹, (CH₂)ₙS(O)ᵘR¹⁰, (CH₂)ₙOC(O)R¹⁰, (CH₂)ₙC(O)R¹⁰, (CH₂)ₙSR⁸, CH=N-OA, CH₂CH=N-OA, (CH₂)ₙNHOA, (CH₂)ₙCH=N-R⁸, (CH₂)ₙOC(O)NR⁸R⁹, (CH₂)ₙNR⁸COOR¹⁰, (CH₂)ₙN(R⁸)CH₂CH₂OR¹⁰, (CH₂)ₙN(R⁸)CH₂CH₂OCF₃, CH₂)ₙN(R⁸)C(R¹⁰)HCOOR⁹, (CH₂)ₙN(R⁸)C(R¹⁰)HCOR⁹, (CH₂)ₙN(R⁸)CH₂CH₂N(R⁹)CH₂COOR⁸, (CH₂)ₙN(R⁸)CH₂CH₂NR⁸R⁹, CH=CHCOOR¹⁰, CH=CHCH₂NR⁸R⁹, CH=CHCH₂NR⁸R⁹, CH=CHCH₂OR¹⁰, (CH₂)ₙN(COOR¹⁰)COOR¹¹, (CH₂)ₙN(CONH₂)COOR¹⁰, (CH₂)ₙN(CONH₂)CONH₂, (CH₂)ₙN(CH₂COOR¹⁰)COOR¹¹, (CH₂)ₙN(CH₂CONH₂)COOR¹⁰, (CH₂)ₙN(CH₂CONH₂)CONH₂, (CH₂)ₙCHR¹⁰COR¹¹, (CH₂)ₙCHR¹⁰COOR¹¹, (CH₂)ₙCHR¹⁰CH₂OR¹¹, (CH₂)ₙOCN y (CH₂)ₙNCO; R⁸, R⁹ están seleccionados, de modo independiente entre sí, del grupo que consiste en H, A, (CH₂)ₘAr¹ y (CH₂)ₘHet o en NR⁸R⁹, R⁸ y R⁹ forman, junto con el átomo de N al que están unidos, un heterociclo de 5, 6 ó 7 miembros que opcionalmente contiene 1 ó 2 heteroátomos adicionales seleccionados de N, O y S; R¹⁰, R¹¹ están seleccionados, de modo independiente entre sí, del grupo que consiste en H, Hal, A, (CH₂)ₘAr² y (CH₂)ₘHet; A está seleccionado del grupo que consiste en alquilo, alquenilo y cicloalquilo; Ar¹, Ar² son, de modo independiente entre sí, residuos de hidrocarburos aromáticos que comprenden 5 a 12 y con preferencia, 5 a 10 átomos de carbono que están opcionalmente sustituidos con uno o varios sustituyentes seleccionados de un grupo que consiste en A, Hal, NO₂, CN, OR¹², NR¹²R¹³, COOR¹², CONR¹²R¹³, NR¹²COR¹³, NR¹²CONR¹²R¹³, NR¹²SO₂A, COR¹², SO₂R¹²R¹³, S(O)ᵘA y OOCR¹²; Het es un residuo heterocíclico mono- o bicíclico saturado, insaturado o aromático que contiene 3 a 14 átomos de carbono y 1 ó 4 heteroátomos, seleccionados de modo independiente de N, O y S, que está opcionalmente sustituido con uno o varios sustituyentes seleccionados de un grupo que consiste en A, Hal, NO₂, CN, OR¹², NR¹²R¹³, COOR¹², CONR¹²R¹³, NR¹²COR¹³, NR¹²CONR¹²R¹³, NR¹²SO₂A, COR¹², SO₂R¹²R¹², S(O)ᵘA y OOCR¹²; R¹², R¹³ están seleccionados, de modo independiente entre sí, del grupo que consiste en H, A y (CH₂)ₘAr³; Ar³ es un hidrocarburo aromático de 5 ó 6 miembros que está opcionalmente sustituido con uno o varios sustituyentes seleccionados de un grupo que consiste en metilo, etilo, propilo, 2-propilo, ter.-butilo, Hal, CN, OH, NH₂ y CF₃; k, u, n y m son, de modo independiente entre sí, 0, 1, 2, 3, 4 ó 5; Hal está seleccionado, de modo independiente entre sí, del grupo que consiste en F, Cl, Br y I; y sus sales, solvatos y estereoisómeros fisiológicamente aceptables, incluyendo sus mezclas en todas las proporciones.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12006134 | 2012-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR092266A1 true AR092266A1 (es) | 2015-04-08 |
Family
ID=46832179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130103053A AR092266A1 (es) | 2012-08-29 | 2013-08-28 | Inhibidores de ddr2 para el tratamiento de osteoartritis |
Country Status (9)
Country | Link |
---|---|
US (1) | US20150225369A1 (es) |
EP (1) | EP2890380A2 (es) |
JP (1) | JP2015530378A (es) |
CN (1) | CN104602690A (es) |
AR (1) | AR092266A1 (es) |
AU (1) | AU2013307688A1 (es) |
CA (1) | CA2883172A1 (es) |
IL (1) | IL237321A0 (es) |
WO (1) | WO2014032755A2 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3030250B1 (de) * | 2013-08-06 | 2019-08-28 | Merck Patent GmbH | Intraartikuläre applikation von pepstatin bei arthrose |
WO2016070024A1 (en) * | 2014-10-31 | 2016-05-06 | Washington University | Ddr2 inhibitors and methods of using |
CN107922320A (zh) | 2015-08-31 | 2018-04-17 | 东丽株式会社 | 尿素衍生物和其用途 |
RU2018109256A (ru) * | 2015-08-31 | 2019-10-07 | Торэй Индастриз, Инк. | Производное мочевины и его применение |
MA51285A (fr) | 2017-12-18 | 2021-04-28 | Chiesi Farm Spa | Dérivés d'azaindole comme inhibiteurs de rho-kinase |
WO2019152711A1 (en) | 2018-01-31 | 2019-08-08 | Diciphera Pharmaceuticals Llc. | Combination therapy for the treatment of gastrointestinal stromal tumors |
GB201909194D0 (en) * | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
MX2022001863A (es) | 2019-08-12 | 2022-05-30 | Deciphera Pharmaceuticals Llc | Metodos para tratar los tumores del estroma gastrointestinal. |
HRP20231699T1 (hr) | 2019-12-30 | 2024-05-10 | Deciphera Pharmaceuticals, Llc | Formulacije inhibitora amorfne kinaze i postupci njihove primjene |
IL293864A (en) | 2019-12-30 | 2022-08-01 | Deciphera Pharmaceuticals Llc | Preparations of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3- phenylurea |
AU2021282320A1 (en) | 2020-05-25 | 2022-12-22 | Chiesi Farmaceutici S.P.A. | Benzylamine derivatives as DDRs inhibitors |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4125828A (en) | 1972-08-04 | 1978-11-14 | Med-El Inc. | Method and apparatus for automated classification and analysis of cells |
US4207554A (en) | 1972-08-04 | 1980-06-10 | Med-El Inc. | Method and apparatus for automated classification and analysis of cells |
DE2346939A1 (de) * | 1973-09-18 | 1975-04-03 | Bayer Ag | Acylamino-phenyl-acetamidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
EP0729459B1 (en) * | 1993-11-15 | 2003-03-12 | Schering Corporation | Phenyl-alkyl imidazoles as h3-receptor antagonists |
AU3577995A (en) * | 1994-10-04 | 1996-04-26 | Fujisawa Pharmaceutical Co., Ltd. | Urea derivatives and their use as acat-inhibitors |
RU2196769C2 (ru) * | 1995-08-30 | 2003-01-20 | Джи. Ди. Сирл Энд Ко. | Производные аминобензойной кислоты, фармацевтическая композиция |
NZ331480A (en) * | 1997-09-04 | 2000-02-28 | F | 2-(Arylphenyl)amino-imidazoline derivatives and pharmaceutical compositions |
US5990147A (en) * | 1997-11-07 | 1999-11-23 | Schering Corporation | H3 receptor ligands of the phenyl-alkyl-imidazoles type |
JP2001522835A (ja) * | 1997-11-07 | 2001-11-20 | シェーリング コーポレイション | フェニル−アルキル−イミダゾール型のh3レセプターリガンド |
US7517880B2 (en) * | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
US20120046290A1 (en) * | 1997-12-22 | 2012-02-23 | Jacques Dumas | Inhibition of p38 kinase activity using substituted heterocyclic ureas |
NZ525324A (en) * | 2000-10-20 | 2005-03-24 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
EP1463714A4 (en) * | 2001-12-10 | 2005-10-19 | Amgen Inc | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS |
TW200406374A (en) * | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
US7247741B2 (en) * | 2005-01-21 | 2007-07-24 | Ptc Therapeutics, Inc. | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
WO2004009533A1 (en) * | 2002-07-24 | 2004-01-29 | Ptc Therapeutics, Inc. | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
BR0315580A (pt) * | 2002-10-24 | 2005-08-30 | Merck Patent Gmbh | Derivados de metileno uréia |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
AU2004218463B2 (en) * | 2003-03-03 | 2009-07-16 | Array Biopharma, Inc. | p38 inhibitors and methods of use thereof |
DE10334663A1 (de) * | 2003-07-30 | 2005-03-10 | Merck Patent Gmbh | Harnstoffderivate |
KR20050091462A (ko) | 2004-03-12 | 2005-09-15 | 한국과학기술연구원 | 푸로피리미딘 화합물 및 이를 포함하는 ddr2 티로신키나아제 활성 저해제 |
EP1742908B1 (en) * | 2004-04-23 | 2009-11-11 | F.Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
US20090105218A1 (en) * | 2004-05-29 | 2009-04-23 | 7Tm Pharma A/S | CRTH2 Receptor Ligands For Therapeutic Use |
NZ554017A (en) * | 2004-10-12 | 2010-06-25 | Astrazeneca Ab | [(Quinazolin-4-yloxy)phenyl]acetamide derivatives |
CA2584179C (en) * | 2004-10-13 | 2013-01-29 | Wolfgang Staehle | N,n'-diphenylurea derivatives which are suitable as kinase inhibitors |
EP1809628B1 (de) * | 2004-10-13 | 2011-06-08 | Merck Patent GmbH | Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen |
EP1824843A2 (en) * | 2004-12-07 | 2007-08-29 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
EP1856053A1 (en) * | 2005-01-14 | 2007-11-21 | Millennium Pharmaceuticals, Inc. | Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity |
US7888374B2 (en) * | 2005-01-28 | 2011-02-15 | Abbott Laboratories | Inhibitors of c-jun N-terminal kinases |
EP1970375A4 (en) * | 2005-11-29 | 2010-06-02 | Toray Industries | ARYLMETHYLENE UREE DERIVATIVE AND USE THEREOF |
RU2008127486A (ru) * | 2005-12-08 | 2010-01-20 | Милленниум Фармасьютикалз, Инк. (Us) | Бициклические соединения с ингибиторной активностью в отношении киназы |
WO2007109783A2 (en) * | 2006-03-23 | 2007-09-27 | Janssen Pharmaceutica, N.V. | Substituted pyrimidine kinase inhibitors |
US20090203693A1 (en) * | 2006-06-29 | 2009-08-13 | Eisai R & D Management Co., Ltd. | Therapeutic agent for liver fibrosis |
US8450481B2 (en) * | 2007-06-14 | 2013-05-28 | The Regents Of The University Of California | Compounds for inhibiting protein aggregation, and methods for making and using them |
EP2242367A4 (en) * | 2008-01-08 | 2012-07-04 | Univ Pennsylvania | REL INHIBITORS AND METHODS OF USE |
PT2268623E (pt) * | 2008-03-17 | 2015-09-17 | Ambit Biosciences Corp | Derivados de quinazolina como moduladores de cinase raf e métodos para utilização dos mesmos |
DE102008027574A1 (de) * | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
EA201200218A1 (ru) | 2009-08-06 | 2012-09-28 | Мерк Патент Гмбх | Новые бициклические соединения мочевины |
EP2937345B1 (en) * | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
EP2674161A1 (en) * | 2010-11-11 | 2013-12-18 | Akron Molecules GmbH | FMO3 inhibitors for treating pain |
CA2843330C (en) * | 2011-08-03 | 2016-09-20 | National Taiwan University | Substituted phenyl- and heteroaryl-phenyl ether agonists of src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same |
-
2013
- 2013-07-29 US US14/424,498 patent/US20150225369A1/en not_active Abandoned
- 2013-07-29 EP EP13744968.2A patent/EP2890380A2/en not_active Withdrawn
- 2013-07-29 WO PCT/EP2013/002236 patent/WO2014032755A2/en active Application Filing
- 2013-07-29 CN CN201380045331.0A patent/CN104602690A/zh active Pending
- 2013-07-29 AU AU2013307688A patent/AU2013307688A1/en not_active Abandoned
- 2013-07-29 JP JP2015528896A patent/JP2015530378A/ja active Pending
- 2013-07-29 CA CA2883172A patent/CA2883172A1/en active Pending
- 2013-08-28 AR ARP130103053A patent/AR092266A1/es unknown
-
2015
- 2015-02-19 IL IL237321A patent/IL237321A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2015530378A (ja) | 2015-10-15 |
EP2890380A2 (en) | 2015-07-08 |
WO2014032755A3 (en) | 2014-07-17 |
CN104602690A (zh) | 2015-05-06 |
WO2014032755A2 (en) | 2014-03-06 |
AU2013307688A1 (en) | 2015-04-09 |
CA2883172A1 (en) | 2014-03-06 |
US20150225369A1 (en) | 2015-08-13 |
IL237321A0 (en) | 2015-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR092266A1 (es) | Inhibidores de ddr2 para el tratamiento de osteoartritis | |
AR098136A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
AR094452A1 (es) | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa | |
AR091193A1 (es) | HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg | |
AR093403A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa | |
AR093404A1 (es) | Compuestos macrociclicos que modulan la actividad de los inhibidores de la apoptosis | |
AR092568A1 (es) | Derivados triciclicos de quinolinas y de quinoxalinas | |
AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
AR089865A1 (es) | Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio | |
AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR095422A1 (es) | Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina | |
AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
AR091023A1 (es) | Inhibidores del nampt | |
ES2659397T3 (es) | 2-azabicíclicos sustituidos y su uso como moduladores receptores de orexinas | |
AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
NI201500129A (es) | 7-azabiciclos sustituidos y su uso como moduladores del receptor de orexina. | |
AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
ES2587953T3 (es) | Amidas cíclicas como inhibidores de MetAP-2 | |
AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
AR091022A1 (es) | Inhibidores del nampt | |
AR098147A1 (es) | Composiciones herbicidas que contienen amidas de ácido n-(1,3,4-oxadiazol-2-il)arilcarboxílico | |
AR090587A1 (es) | Compuestos triciclicos sustituidos con actividad hacia los receptores ep1 | |
AR068658A1 (es) | Derivados de tiazol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |